> IX International Symposium of the Spanish Research Group in Breast Cancer (GEICAM) and the increasing presence of Genomic Platforms
Palex Medical through its Oncology Division has been one of the sponsorships of the IX International Symposium of the Spanish Research Group in Breast Cancer (GEICAM), held in Valencia between the 18th and 19th of April
During the symposium one of the topics was the increased use of Genomic Platforms, which have a remarkable impact in the field of breast cancer approach. Genomic Platforms fulfill three important objectives: Identify the underlying biology of the tumor, predict the risk of recurrence of this tumor and identify which patients would benefit from chemotherapy.
Experts stress that Spain is very well placed in this field, since these tests are comercially available in the Spanish territory. Although only Oncotype DX for Breast Cancer is scientifically validated to predict the benefit of the chemotherapy in a specific group of patients.
The forum also noted that only four regions (Catalonia, Valencia, Madrid and the Basque Country) have approved the use of Genomic platforms in Public Health Sytem. This situation would produce inequity from the patients perspective.